FOLLOW-UP OF METHOTREXATE EFFECTIVENESS IN A PATIENT WITH JUVENILE POLYARTHRITIS
https://doi.org/10.15690/pf.v11i4.1073
Abstract
The article presents a short review of the current notion of the leading role methotrexate in treatment of most clinical variants of
juvenile idiopathic arthritis. The authors demonstrate that methotrexate is a “gold standard” of antirheumatic therapy and the key disease-modifying drug of pediatric rheumatology. The emphasis is laid on safety profile and advantages of parenteral administration thereof. The article presents follow-up of a clinical case involving use of dosage form of methotrexate in the dose of 15 mg/m per week for subcutaneous administration in a patient with polyarticular juvenile idiopathic arthritis featuring insufficient effectiveness and low tolerance of the oral drug. Prescription of methotrexate for subcutaneous administration helped to terminate progression of the disease and pain syndrome and improve function of the affected joints and the patient’s quality of life.
About the Authors
L. A. Balykova
Ogaryov Mordovian State University, Saransk, Russian Federation
Russian Federation
Russian Federation
O. M. Soldatov
Republican Pediatric Clinical Hospital No. 2, Saransk, Republic of Mordovia, Russian Federation
Russian Federation
Russian Federation
N. V. Shchekina
Republican Pediatric Clinical Hospital No. 2, Saransk, Republic of Mordovia, Russian Federation
Russian Federation
Russian Federation
A. V. Krasnopol'skaya
Ogaryov Mordovian State University, Saransk, Russian Federation
Russian Federation
Russian Federation
A. N. Os'kina
Ogaryov Mordovian State University, Saransk, Russian Federation
Russian Federation
Russian Federation
References
1. Vidqvist K.L., Malin M., Varjolahti-Lehtinen T., Korpela M.M. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology (Oxford). 2013 Nov; 52 (11): 1999−2003.
2. Kahn P. Juvenile idiopathic arthritis: an update for the clinician. Bull NYU Hosp Jt Dis. 2012; 70 (3): 152−166.
3. Tynjälä P., Vähäsalo P., Tarkiainen M., Kröger L., Aalto K., Malin M., Putto-Laurila A., Honkanen V., Lahdenne P. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011 Sep; 70 (9): 1605−1612.
4. Harris J.G., Kessler E.A., Verbsky J.W. Update on the treatment of juvenile idiopathic arthritis. Curr Allergy Asthma Rep. 2013 Aug; 13 (4): 337−346.
5. Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., DeWitt E.M., Ilowite N.T., Kimura Y., Laxer R.M., Lovell D.J. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011; 12 (4): 465–482.
6. Holzinger D., Frosch M., Föll D. Methotrexate in the therapy of juvenile idiopathic arthritis. Z Rheumatol. 2010 Aug; 69 (6): 496−504.
7. Lopez-Olivo M.A., Siddhanamatha H.R., Shea B., Tugwell P., Wells G.A., Suarez-Almazor M.E. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014 Jun 10; 6: CD000957.
8. Nasonov E.L. Metotreksat. Perspektivy primeneniya v revmatologii [Methotrexate. Prospects for Application in Dermatology]. Moscow, 2005. P. 16–28.
9. Niedel J., Sova L., Schroers B. Effect of methotrexate on normal articular cartilage in vitro and in vivo. Ann Rheum Dis.1998; 57: 414–421.
10. Cronstein N.B., Levine R.E., Philips M.R. et al. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immun. 1992; 148: 2201–2206.
11. Beukelman T., Ringold S., Davis T.E., DeWitt E.M., Pelajo C.F., Weiss P.F., Kimura Y. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol. 2012; 12 (9): 1867–1874.
12. van der Heijde D., Sieper J., Maksymowych W.P., Dougados M., Burgos-Vargas R., Landewe R., Rudwaleit M., Braun J. 2010 Update of the international ASAS recommenda-tions for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; 12 (6): 905–908.
13. Ramanathan A., Srinivasalu H., Colbert R.A. Update on juvenile spondyloarthritis. Rheum Dis Clin North Am. 2013; 12 (4): 767–788.
14. Giannini E.H., Brewer E.J., Kuzmina N., Shaikov A., Maximov A., Vorontsov I., Fink C.W., Newman A.J., Cassidy J.T., Zemel L.S. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA−USSR. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992; 12 (16): 1043–1049.
15. Woo P., Southwood T.R., Prieur A.M., Dore C.J., Grainger J., David J. et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43: 1849–1857.
16. Riddle R., Ryser C.N., Morton A.A., Sampson J.D., Browne R.H., Punaro M.G. et al. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol. 2006; 31: 262–271.
17. Schmeling H., Foeldvari I., Horneff G. A39: efficacy and safety of methotrexate in oligo-articular persistent juvenile idiopathic arthritis. Arthritis Rheumatol. 2014 Mar; 66 (Suppl. 11): S59.
18. Salliot C., van der Heijde D. Long term safety of methotrexate monotherapy in rheumato-id arthritis patients: a systematic literature research. Ann Rheum Dis. 2009; 68: 1100–1104.
19. Shea B., Swinden M.V., Ghogomu E.T., Ortiz Z., Katchamart W., Rader T., Bombardier C., Wells G.A., Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014 Jun; 41 (6): 1049−1060.
20. Klein A., Kaul I., Foeldvari I., Ganser G., Urban A., Horneff G. Efficacy and safety of oral and parenteral from the German Methotrexate Registry. Arthritis Care Res (Hoboken). 2012; 12 (9): 1349–1356.
21. Bechard M., Lemieux J., Roth J., Duffy K.W., Duffy C.M., Aglipay M., Barrowman N., Jurencak R. A64: patient-reported side effects with weekly injections of methotrexa-te in tertiary care rheumatology clinic. Arthritis.Rheumatol. 2014 Mar; 66 (Suppl. 11): S94.
22. Tukova J., Chladek J., Nemcova D., Chladkova J., Dolezalova P. Methotrexate bioavailability after oral and subcutaneous аdministration in children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2009; 12 (6): 1047–1053.
23. Hoekstra M., Haagsma C., Neef C. et al. Bioavailability of higher dose methotrexate cjmparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheum. 2004; 31: 645–648.
24. Linde L., Hetland M.L., Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. Scand J Rheum. 2006; 35: 102–106.
25. Alsufyani K., Ortiz-Alvarez O., Cabral D.A., Tucker L.B., Petty R.E., Malleson P.N. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol. 2004; 12 (1): 179–182.
26. Ruperto N., Murray K.J., Gerloni V., Wulffraat N., de Oliveira S.K., Falcini F., Dolezalova P., Alessio M., Burgos-Vargas R., Corona F., Vesely R., Foster H., Davidson J., Zulian F., Asplin L., Baildam E., Consuegra J.G., Ozdogan H., Saurenmann R., Joos R., Pistorio A., Woo P., Martini A. A randomized trial of parenteral methotrexate comparing an inter-mediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 12 (7): 2191−2201.
27. Becker M.L., Rose C.D., Cron R.Q., Sherry D.D., Bilker W.B., Lautenbach E. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol. 2010; 12 (4): 870–875.
28. Niehues T., Lankisch P. Recommendations for the use of methotrexate in juvenile idiopa- thic arthritis. Paediatr Drugs. 2006; 8 (6): 347−356.
29. Visser K., Katchamart W., Loza E. et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009; 68: 1086–1093.
30. Braun J., Kaestner P., Flaxenberg P. еt al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthrit Rheum. 2008; 58: 73–81.
Review
For citations:
Balykova L.A., Soldatov O.M., Shchekina N.V., Krasnopol'skaya A.V., Os'kina A.N. FOLLOW-UP OF METHOTREXATE EFFECTIVENESS IN A PATIENT WITH JUVENILE POLYARTHRITIS. Pediatric pharmacology. 2014;11(4):103-108. (In Russ.) https://doi.org/10.15690/pf.v11i4.1073
Views:
688
Email this article 